Inspire therapy works inside the body with a patient’s natural breathing process to treat sleep apnea. Mild stimulation keeps the airway open during sleep, allowing oxygen to flow naturally. The patient uses a small handheld remote to turn Inspire on before bed and off when they wake up. No mask, no noise, no hose.
94% Patient Satisfaction
Inspire therapy was FDA approved in 2014. It has been proven both safe and effective in multiple long-term studies.
79% Reduction in Apnea
The Inspire obstructive sleep apnea device significantly reduces snoring and daytime sleepiness.
The Inspire system is inserted under the skin through three small incisions during an outpatient procedure. Most patients return home the same day and are able to return to non-strenuous activities almost immediately. Most people take over-the-counter pain medicine for a few days after the procedure for pain management.
Inspire patients are in complete control of their Inspire using the Inspire Sleep Remote. Patients keep the Inspire Sleep Remote in a convenient space next to their bed and turn the device on when they go to sleep, off when they wake up or pause the therapy if they want to. In addition, they can increase or decrease the strength of the mild stimulation to find the setting that gives them comfortable, restful sleep. With the Inspire Sleep Remote, patients use Inspire all night, every night.
Inspire is for patients who:
Have been diagnosed with moderate to severe Obstructive Sleep Apnea (AHI – the number of times they wake up each hour – between 15-65)
Are unable to use or get consistent benefit from CPAP
Are not significantly overweight
Are over age 22
Inspire therapy was FDA-approved in 2014 and is in use by over 4,000 patients worldwide. Over 200 leading medical centers have now been trained to offer Inspire as part of their sleep apnea treatment options.
Clinical Results
The safety and efficacy of Inspire therapy was measured during the STAR clinical trial. One-year STAR trial results were published in January 9th, 2014 edition of the New England Journal of Medicine, showing patients using Inspire therapy had significant reductions in sleep apnea events and significant improvements in quality of life measures. These significant reductions and improvements were sustained over a 5-year follow-up period.
As of February 2019, there have been over 70 peer-reviewed publications on Inspire therapy. These publications show that patients using Inspire therapy in real world, clinical practice settings experience significant reductions in sleep apnea events and significant improvements in quality of life measures, consistent with those seen in the STAR clinical trial.
Dr. Langford is board certified by the American Board of Otolaryngology – Head and Neck Surgery.
Special interests include pediatric ENT, allergy/sinus surgery including balloon sinuplasty, head and neck cancer (including thyroid, parathyroid, and parotid surgery), ear disease, and sleep apnea.
To learn more about Inspire Therapy, visit https://www.inspiresleep.com/